The estimated Net Worth of Sheldon L. Koenig is at least $1.14 Million dollars as of 9 May 2023. Mr Koenig owns over 20,000 units of Esperion Therapeutics stock worth over $544,300 and over the last 6 years he sold ESPR stock worth over $88,874. In addition, he makes $507,639 as Pres und CEO & Director at Esperion Therapeutics.
Mr has made over 7 trades of the Esperion Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of ESPR stock worth $25,200 on 9 May 2023.
The largest trade he's ever made was buying 20,000 units of Esperion Therapeutics stock on 9 May 2023 worth over $25,200. On average, Mr trades about 2,609 units every 22 days since 2019. As of 9 May 2023 he still owns at least 312,816 units of Esperion Therapeutics stock.
You can see the complete history of Mr Koenig stock trades at the bottom of the page.
Sheldon L. Koenig is the Pres, CEO & Director at Esperion Therapeutics.
As the Pres und CEO & Director of Esperion Therapeutics, the total compensation of Mr Koenig at Esperion Therapeutics is $507,639. There are 4 executives at Esperion Therapeutics getting paid more, with Timothy Mayleben having the highest compensation of $1,080,850.
Mr Koenig is 55, he's been the Pres und CEO & Director of Esperion Therapeutics since . There are 6 older and 9 younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics Inc. is Antonio Gotto, 84, who is the Independent Director.
Sheldon's mailing address filed with the SEC is C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108.
Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio... und Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Esperion Therapeutics executives and other stock owners filed with the SEC include: